Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PARK with free AI briefings, catalyst countdowns, and dilution alerts.

PARK · Park Dental Partners, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$23.2M Cash on Hand
CF+ Cash Runway
Follow PARK by email Get an email when PARK reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PARK, unsubscribe in one click. Privacy

📣 What PARK Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

PARK holds $23.2M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PARK files for a raise →

👥 Who Owns PARK

Insiders 12.6% Institutions (29 holders) 21.6% Public and other holders 65.8%
HolderTypeShares% of sharesAs of
Peter G Swenson
CEO and Chairman, Director · +23,785 options
Insider 238,381 4.31% 2025-12-03
Alan Siems Law
Chief Clinical Officer - Specialty Pract · +7,796 options
Insider 180,961 3.27% 2026-08-25
Christopher Eugene Steele
Chief Clinical Officer - General Practic · +5,855 options
Insider 137,172 2.48% 2025-12-02
Todd Christopher Gerlach
Director
Insider 68,847 1.24% 2025-12-03
Christopher James Bernander
Chief Financial Officer, Director · +11,184 options
Insider 55,756 1.01% 2025-12-03
Christopher Charles Smith
Director · +2,632 options
Insider 10,492 0.19% 2025-12-03
Philip Irving Smith
Director · +2,632 options
Insider 3,569 0.06% 2025-12-03
Anna Marie Schaefer
Director · +2,632 options
Insider 2,800 0.05% 2025-12-02

Share count 5,535,029 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PARK picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PARK and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.